DETAILS, FICTION AND PAOPA

There have been no clinically considerable variations in the pharmacokinetics of either midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when made use of concomitantly with finerenone. A number of doses of forty mg finerenone after-day by day had no clinically applicable effect on AUC or Cmax from the BCRP and OATP substrate rosuvasta